{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,10]],"date-time":"2026-09-10T14:55:44Z","timestamp":1789052144855,"version":"build-2803163510"},"reference-count":71,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2026,3,16]],"date-time":"2026-03-16T00:00:00Z","timestamp":1773619200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2026,4,23]],"date-time":"2026-04-23T00:00:00Z","timestamp":1776902400000},"content-version":"vor","delay-in-days":38,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"funder":[{"DOI":"10.13039\/501100003977","name":"Israel Science Foundation","doi-asserted-by":"publisher","award":["1266\/24"],"award-info":[{"award-number":["1266\/24"]}],"id":[{"id":"10.13039\/501100003977","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Mol Med"],"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:sec>\n                    <jats:title>Background<\/jats:title>\n                    <jats:p>\n                      Autosomal dominant polycystic kidney disease (ADPKD) is characterized by progressive cyst formation, inflammation, and metabolic dysregulation. The endocannabinoid system (ECS), particularly the cannabinoid-1 receptor (CB\n                      <jats:sub>1<\/jats:sub>\n                      R), regulates renal metabolism and inflammatory signaling, yet its role in ADPKD remains largely unexplored.\n                    <\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods<\/jats:title>\n                    <jats:p>\n                      We analyzed publicly available human kidney transcriptomic datasets (bulk microarray GSE7869; single-nucleus RNA-sequencing from ADPKD GSE185948, and diabetic kidney disease cohorts GSE195460) and validated findings in ADPKD patient kidney tissue versus non-cystic controls using quantitative PCR, liquid chromatography-tandem mass spectrometry, and Western blotting. Longitudinal disease progression was evaluated in\n                      <jats:italic>Pkd1<\/jats:italic>\n                      <jats:sup>RC\/RC<\/jats:sup>\n                      mice at 3, 6, 9, and 12\u00a0months, with comprehensive assessment of ECS components, endocannabinoid (eCB) levels, and kidney function parameters. Correlation examined associations between ECS markers and disease severity.\n                    <\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>\n                      Human ADPKD kidneys demonstrated consistent upregulation of\n                      <jats:italic>CNR1<\/jats:italic>\n                      transcripts across platforms, with single-nucleus analysis revealing enrichment in proximal tubule-derived populations including failed-repair proximal tubule cells. ADPKD tissue exhibited significant reductions in key ECS-metabolizing enzymes (\n                      <jats:italic>FAAH<\/jats:italic>\n                      ,\n                      <jats:italic>NAPEPLD<\/jats:italic>\n                      ,\n                      <jats:italic>MGLL<\/jats:italic>\n                      ) and marked depletion of eCB ligands anandamide (AEA) and 2-arachidonoylglycerol (2-AG). In contrast, diabetic kidney disease showed minimal ECS alterations, indicating ADPKD-specific dysregulation.\n                      <jats:italic>Pkd1<\/jats:italic>\n                      <jats:sup>RC\/RC<\/jats:sup>\n                      mice recapitulated human findings, with\n                      <jats:italic>Cnr1<\/jats:italic>\n                      upregulation beginning at 6 months and significant AEA\/\n                      <jats:italic>N<\/jats:italic>\n                      -oleoylethanolamine (OEA) depletion at 9\u201312 months. CB\n                      <jats:sub>1<\/jats:sub>\n                      R protein elevation preceded ligand depletion, suggesting progressive receptor sensitization. Correlation analyses revealed robust associations between CB\n                      <jats:sub>1<\/jats:sub>\n                      R\/enzyme expression, eCB depletion, and declining kidney function (kidney weight-to-body weight ratio, blood urea nitrogen, and creatinine clearance).\n                    <\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusions<\/jats:title>\n                    <jats:p>\n                      ADPKD kidneys exhibit disease-specific dysregulation of the ECS, characterized by increased CB\n                      <jats:sub>1<\/jats:sub>\n                      R expression accompanied by paradoxical depletion of eCB ligands. These alterations correlate with cyst burden and functional decline across human and murine disease stages, identifying the ECS as a prominently affected pathway during ADPKD progression. While our findings establish a strong association between ECS dysregulation and disease severity, whether altered CB\n                      <jats:sub>1<\/jats:sub>\n                      R signaling represents a causal driver of cystogenesis or a secondary, yet therapeutically targetable component of the cystic and injury response will require direct genetic or pharmacologic modulation of CB\n                      <jats:sub>1<\/jats:sub>\n                      R\/ECS signaling.\n                    <\/jats:p>\n                  <\/jats:sec>","DOI":"10.1186\/s10020-026-01457-w","type":"journal-article","created":{"date-parts":[[2026,3,16]],"date-time":"2026-03-16T09:26:06Z","timestamp":1773653166000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":2,"title":["Progressive endocannabinoid system dysregulation in autosomal dominant polycystic kidney disease"],"prefix":"10.1186","volume":"32","author":[{"ORCID":"https:\/\/orcid.org\/0009-0005-9208-9456","authenticated-orcid":false,"given":"Shridhar","family":"Betkar","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-2598-0119","authenticated-orcid":false,"given":"Alina","family":"Nemirovski","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-9405-0049","authenticated-orcid":false,"given":"Shmuel","family":"Ruppo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-0307-4350","authenticated-orcid":false,"given":"Liad","family":"Hinden","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-0948-0093","authenticated-orcid":false,"given":"Joseph","family":"Tam","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2026,3,16]]},"reference":[{"key":"1457_CR1","doi-asserted-by":"publisher","first-page":"F325","DOI":"10.1152\/ajprenal.00097.2025","volume":"329","author":"E Abergel","year":"2025","unstructured":"Abergel E, Pri-Chen H, Wallach-Dayan S, Hinden L, Tam J, Volovelsky O, Nechama M (2025) Targeting the endocannabinoid system to suppress mTORC1 hyperactivation in TSC-associated kidney disease. Am J Physiol Renal Physiol 329:F325-F334. https:\/\/doi.org\/10.1152\/ajprenal.00097.2025","journal-title":"Am J Physiol Renal Physiol"},{"key":"1457_CR2","doi-asserted-by":"publisher","first-page":"1704","DOI":"10.1096\/fj.05-3995fje","volume":"19","author":"T Aguado","year":"2005","unstructured":"Aguado T, Monory K, Palazuelos J, Stella N, Cravatt B, Lutz B, Marsicano G, Kokaia Z, Guzman M, Galve-Roperh I (2005) The endocannabinoid system drives neural progenitor proliferation. FASEB J 19:1704-1706. https:\/\/doi.org\/10.1096\/fj.05-3995fje","journal-title":"FASEB J"},{"key":"1457_CR3","doi-asserted-by":"crossref","unstructured":"Arceri L, Nguyen TK, Gibson S, Baker S, Wingert RA (2023) Cannabinoid Signaling in Kidney Disease. Cells 12.","DOI":"10.3390\/cells12101419"},{"key":"1457_CR4","doi-asserted-by":"publisher","first-page":"72","DOI":"10.1016\/j.ceb.2017.02.012","volume":"45","author":"I Ben-Sahra","year":"2017","unstructured":"Ben-Sahra I, Manning BD (2017) mTORC1 signaling and the metabolic control of cell growth. Curr Opin Cell Biol 45:72-82. https:\/\/doi.org\/10.1016\/j.ceb.2017.02.012","journal-title":"Curr Opin Cell Biol"},{"key":"1457_CR5","doi-asserted-by":"publisher","first-page":"50","DOI":"10.1038\/s41572-018-0047-y","volume":"4","author":"C Bergmann","year":"2018","unstructured":"Bergmann C, Guay-Woodford LM, Harris PC, Horie S, Peters DJM, Torres VE (2018) Polycystic kidney disease. Nat Rev Dis Primers 4:50. https:\/\/doi.org\/10.1038\/s41572-018-0047-y","journal-title":"Nat Rev Dis Primers"},{"key":"1457_CR6","doi-asserted-by":"publisher","first-page":"753418","DOI":"10.3389\/fmed.2022.753418","volume":"9","author":"MJ Caplan","year":"2022","unstructured":"Caplan MJ (2022) AMPK and Polycystic Kidney Disease Drug Development: An Interesting Off-Target Target. Front Med (Lausanne) 9:753418. https:\/\/doi.org\/10.3389\/fmed.2022.753418","journal-title":"Front Med"},{"key":"1457_CR7","doi-asserted-by":"publisher","unstructured":"Chen CY, Hadla M, Khambati I, Kashyap S, Westerfield V, Fedeles S, Besse W, Hopp K, Harris PC, Patel V, et al. (2025) Emerging Therapies in Autosomal Dominant Polycystic Kidney Disease. Kidney 360. https:\/\/doi.org\/10.34067\/KID.0000001109","DOI":"10.34067\/KID.0000001109"},{"key":"1457_CR8","doi-asserted-by":"publisher","first-page":"1958","DOI":"10.1681\/ASN.2015030231","volume":"27","author":"M Chiaravalli","year":"2016","unstructured":"Chiaravalli M, Rowe I, Mannella V, Quilici G, Canu T, Bianchi V, Gurgone A, Antunes S, D'Adamo P, Esposito A, et al. (2016) 2-Deoxy-d-Glucose Ameliorates PKD Progression. J Am Soc Nephrol 27:1958-1969. https:\/\/doi.org\/10.1681\/ASN.2015030231","journal-title":"J Am Soc Nephrol"},{"key":"1457_CR9","doi-asserted-by":"publisher","first-page":"10","DOI":"10.1089\/can.2018.0060","volume":"4","author":"JT Chua","year":"2019","unstructured":"Chua JT, Argueta DA, DiPatrizio NV, Kovesdy CP, Vaziri ND, Kalantar-Zadeh K, Moradi H (2019) Endocannabinoid System and the Kidneys: From Renal Physiology to Injury and Disease. Cannabis Cannabinoid Res 4:10-20. https:\/\/doi.org\/10.1089\/can.2018.0060","journal-title":"Cannabis Cannabinoid Res"},{"key":"1457_CR10","unstructured":"ClinicalTrials.gov.A Study of RGLS4326 in Subjects With Autosomal Dominant Polycystic Kidney Disease. Identifier: NCT04536688 Available from: https:\/\/clinicaltrials.gov\/study\/NCT04536688"},{"key":"1457_CR11","unstructured":"ClinicalTrials.gov.A Study of RGLS8429 in Subjects With Autosomal Dominant Polycystic Kidney Disease. Identifier: NCT05429073 Available from: https:\/\/clinicaltrials.gov\/study\/NCT05429073"},{"key":"1457_CR12","doi-asserted-by":"publisher","first-page":"720734","DOI":"10.3389\/fendo.2021.720734","volume":"12","author":"M Dao","year":"2021","unstructured":"Dao M, Fran\u00e7ois H (2021) Cannabinoid Receptor 1 Inhibition in Chronic Kidney Disease: A New Therapeutic Toolbox. Front Endocrinol (Lausanne) 12:720734. https:\/\/doi.org\/10.3389\/fendo.2021.720734","journal-title":"Front Endocrinol (Lausanne)"},{"key":"1457_CR13","doi-asserted-by":"publisher","first-page":"9431","DOI":"10.1021\/acs.jmedchem.4c03132","volume":"68","author":"A Gammal","year":"2025","unstructured":"Gammal A, Nassar T, Soae Y, Freeman N, Badihi A, Baraghithy S, Nemirovski A, Tam J, Benita S (2025) Synthesis and Pharmacological Characterization of Novel Peripheral Cannabinoid-1 Receptor Blockers Based on a Tricyclic Scaffold. J Med Chem 68: 9431-9445. https:\/\/doi.org\/10.1021\/acs.jmedchem.4c03132","journal-title":"J Med Chem"},{"key":"1457_CR14","doi-asserted-by":"publisher","first-page":"e21232","DOI":"10.1096\/fj.202001960R","volume":"35","author":"JH Han","year":"2021","unstructured":"Han JH, Kim W (2021) Peripheral CB1R as a modulator of metabolic inflammation. FASEB J 35:e21232. https:\/\/doi.org\/10.1096\/fj.202001960","journal-title":"FASEB J"},{"key":"1457_CR15","doi-asserted-by":"publisher","first-page":"155","DOI":"10.1038\/npp.2017.130","volume":"43","author":"CJ Hillard","year":"2018","unstructured":"Hillard CJ (2018) Circulating Endocannabinoids: From Whence Do They Come and Where are They Going? Neuropsychopharmacology 43:155-172. https:\/\/doi.org\/10.1038\/npp.2017.130","journal-title":"Neuropsychopharmacology"},{"key":"1457_CR16","doi-asserted-by":"publisher","first-page":"1783","DOI":"10.1038\/s41467-022-29124-8","volume":"13","author":"L Hinden","year":"2022","unstructured":"Hinden L, Ahmad M, Hamad S, Nemirovski A, Szanda G, Glasmacher S, Kogot-Levin A, Abramovitch R, Thorens B, Gertsch J, et al. (2022) Opposite physiological and pathological mTORC1-mediated roles of the CB1 receptor in regulating renal tubular function. Nat Commun 13:1783. https:\/\/doi.org\/10.1038\/s41467-022-29124-8","journal-title":"Nat Commun"},{"key":"1457_CR17","doi-asserted-by":"publisher","first-page":"254","DOI":"10.1016\/j.jconrel.2022.11.040","volume":"353","author":"S Hirsch","year":"2023","unstructured":"Hirsch S, Hinden L, Naim MB, Baraghithy S, Permyakova A, Azar S, Nasser T, Portnoy E, Agbaria M, Nemirovski A, et al. (2023) Hepatic targeting of the centrally active cannabinoid 1 receptor (CB(1)R) blocker rimonabant via PLGA nanoparticles for treating fatty liver disease and diabetes. J Control Release 353:254-269. https:\/\/doi.org\/10.1016\/j.jconrel.2022.11.040","journal-title":"J Control Release"},{"key":"1457_CR18","doi-asserted-by":"publisher","first-page":"154","DOI":"10.2215\/CJN.0000000000000055","volume":"18","author":"MC Hogan","year":"2023","unstructured":"Hogan MC, Masyuk TV (2023) Concurrent Targeting of Vasopressin Receptor 2 and Somatostatin Receptors in Autosomal Dominant Polycystic Kidney Disease: A Promising Approach for Autosomal Dominant Polycystic Kidney Disease Treatment? Clin J Am Soc Nephrol 18:154-156. https:\/\/doi.org\/10.2215\/CJN.0000000000000055","journal-title":"Clin J Am Soc Nephrol"},{"key":"1457_CR19","doi-asserted-by":"publisher","first-page":"4257","DOI":"10.1172\/JCI64313","volume":"122","author":"K Hopp","year":"2012","unstructured":"Hopp K, Ward CJ, Hommerding CJ, Nasr SH, Tuan HF, Gainullin VG, Rossetti S, Torres VE, Harris PC (2012) Functional polycystin-1 dosage governs autosomal dominant polycystic kidney disease severity. J Clin Invest 122:4257-4273. https:\/\/doi.org\/10.1172\/jci64313","journal-title":"J Clin Invest"},{"key":"1457_CR20","doi-asserted-by":"publisher","first-page":"E5420","DOI":"10.1073\/pnas.1419901111","volume":"111","author":"T Jourdan","year":"2014","unstructured":"Jourdan T, Szanda G, Rosenberg AZ, Tam J, Earley BJ, Godlewski G, Cinar R, Liu Z, Liu J, Ju C, et al. (2014) Overactive cannabinoid 1 receptor in podocytes drives type 2 diabetic nephropathy. Proc Natl Acad Sci U S A 111:E5420-5428. https:\/\/doi.org\/10.1073\/pnas.1419901111","journal-title":"Proc Natl Acad Sci U S A"},{"key":"1457_CR21","doi-asserted-by":"publisher","first-page":"698","DOI":"10.1111\/dom.13150","volume":"20","author":"T Jourdan","year":"2018","unstructured":"Jourdan T, Park JK, Varga ZV, Paloczi J, Coffey NJ, Rosenberg AZ, Godlewski G, Cinar R, Mackie K, Pacher P, et al. (2018) Cannabinoid-1 receptor deletion in podocytes mitigates both glomerular and tubular dysfunction in a mouse model of diabetic nephropathy. Diabetes Obes Metab 20:698-708. https:\/\/doi.org\/10.1111\/dom.13150","journal-title":"Diabetes Obes Metab"},{"issue":"107","key":"1457_CR22","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1016\/j.kint.2024.07.009","volume":"2025","author":"Kidney Disease: Improving Global Outcomes, A.W.G","year":"2025","unstructured":"Kidney Disease: Improving Global Outcomes AWG (2025) KDIGO 2025 Clinical Practice Guideline for the Evaluation, Management, and Treatment of Autosomal Dominant Polycystic Kidney Disease (ADPKD). Kidney Int 107:S1-S239. https:\/\/doi.org\/10.1016\/j.kint.2024.07.009","journal-title":"Kidney Int"},{"key":"1457_CR23","doi-asserted-by":"publisher","first-page":"561","DOI":"10.1002\/jgm.1473","volume":"12","author":"C Kilkenny","year":"2010","unstructured":"Kilkenny C, Browne W, Cuthill IC, Emerson M, Altman DG, Group NCRRGW (2010) Animal research: reporting in vivo experiments: the ARRIVE guidelines. J Gene Med 12:561-563. https:\/\/doi.org\/10.1002\/jgm.1473","journal-title":"J Gene Med"},{"key":"1457_CR24","doi-asserted-by":"publisher","first-page":"13","DOI":"10.1007\/978-981-10-2041-4_2","volume":"933","author":"DY Kim","year":"2016","unstructured":"Kim DY, Park JH (2016) Genetic Mechanisms of ADPKD. Adv Exp Med Biol 933: 13-22. https:\/\/doi.org\/10.1007\/978-981-10-2041-4_2","journal-title":"Adv Exp Med Biol"},{"key":"1457_CR25","doi-asserted-by":"publisher","first-page":"F726","DOI":"10.1152\/ajprenal.00551.2015","volume":"310","author":"KR Kipp","year":"2016","unstructured":"Kipp KR, Rezaei M, Lin L, Dewey EC, Weimbs T (2016) A mild reduction of food intake slows disease progression in an orthologous mouse model of polycystic kidney disease. Am J Physiol Renal Physiol 310:F726-f731. https:\/\/doi.org\/10.1152\/ajprenal.00551.2015","journal-title":"Am J Physiol Renal Physiol"},{"key":"1457_CR26","doi-asserted-by":"publisher","first-page":"15874","DOI":"10.1073\/pnas.2005477117","volume":"117","author":"Y Kirita","year":"2020","unstructured":"Kirita Y, Wu H, Uchimura K, Wilson PC, Humphreys BD (2020) Cell profiling of mouse acute kidney injury reveals conserved cellular responses to injury. Proc Natl Acad Sci U S A 117:15874-15883. https:\/\/doi.org\/10.1073\/pnas.2005477117","journal-title":"Proc Natl Acad Sci U S A"},{"key":"1457_CR27","doi-asserted-by":"publisher","first-page":"264","DOI":"10.1159\/000522113","volume":"53","author":"J Klawitter","year":"2022","unstructured":"Klawitter J, Sempio C, Jackson MJ, Smith PH, Hopp K, Chonchol M, Gitomer BY, Christians U, Klawitter J (2022) Endocannabinoid System in Polycystic Kidney Disease. Am J Nephrol 53:264-272. https:\/\/doi.org\/10.1159\/000522113","journal-title":"Am J Nephrol"},{"key":"1457_CR28","doi-asserted-by":"publisher","first-page":"107","DOI":"10.1007\/s00109-015-1337-4","volume":"94","author":"A Kraus","year":"2016","unstructured":"Kraus A, Schley G, Kunzelmann K, Schreiber R, Peters DJ, Stadler R, Eckardt KU, Buchholz B (2016) Glucose promotes secretion-dependent renal cyst growth. J Mol Med (Berl) 94:107-117. https:\/\/doi.org\/10.1007\/s00109-015-1337-4","journal-title":"J Mol Med (Berl)"},{"key":"1457_CR29","doi-asserted-by":"publisher","first-page":"4765","DOI":"10.1038\/s41467-022-32543-2","volume":"13","author":"R Lakhia","year":"2022","unstructured":"Lakhia R, Ramalingam H, Chang CM, Cobo-Stark P, Biggers L, Flaten A, Alvarez J, Valencia T, Wallace DP, Lee EC, et al. (2022) PKD1 and PKD2 mRNA cis-inhibition drives polycystic kidney disease progression. Nat Commun 13:4765. https:\/\/doi.org\/10.1038\/s41467-022-32543-2","journal-title":"Nat Commun"},{"key":"1457_CR30","doi-asserted-by":"publisher","unstructured":"Lakhia R, Song C, Biggers L, Zumwalt M, Alvarez J, Somasundaram A, Ramalingam H, Cobo-Stark P, Patel V (2025) Disruption of a six-nucleotide miRNA motif improves PKD1 dosage and ameliorates polycystic kidney disease. bioRxiv. https:\/\/doi.org\/10.1101\/2025.10.22.683929","DOI":"10.1101\/2025.10.22.683929"},{"key":"1457_CR31","doi-asserted-by":"publisher","first-page":"4148","DOI":"10.1038\/s41467-019-11918-y","volume":"10","author":"EC Lee","year":"2019","unstructured":"Lee EC, Valencia T, Allerson C, Schairer A, Flaten A, Yheskel M, Kersjes K, Li J, Gatto S, Takhar M, et al. (2019) Discovery and preclinical evaluation of anti-miR-17 oligonucleotide RGLS4326 for the treatment of polycystic kidney disease. Nat Commun 10:4148. https:\/\/doi.org\/10.1038\/s41467-019-11918-y","journal-title":"Nat Commun"},{"key":"1457_CR32","doi-asserted-by":"publisher","first-page":"e54633","DOI":"10.1371\/journal.pone.0054633","volume":"8","author":"RF Loeser","year":"2013","unstructured":"Loeser RF, Olex AL, McNulty MA, Carlson CS, Callahan M, Ferguson C, Fetrow JS (2013) Disease progression and phasic changes in gene expression in a mouse model of osteoarthritis. PLoS One 8:e54633. https:\/\/doi.org\/10.1371\/journal.pone.0054633","journal-title":"PLoS ONE"},{"key":"1457_CR33","doi-asserted-by":"publisher","unstructured":"x`Maciejczyk A, Niemczyk M (2025) Metformin as a Disease-Modifying Agent in Autosomal Dominant Polycystic Kidney Disease: A Systematic Review of Preclinical and Clinical Evidence. Curr Issues Mol Biol 47. https:\/\/doi.org\/10.3390\/cimb47090715","DOI":"10.3390\/cimb47090715"},{"key":"1457_CR34","doi-asserted-by":"publisher","first-page":"109468","DOI":"10.1016\/j.cellsig.2019.109468","volume":"66","author":"JP Margaria","year":"2020","unstructured":"Margaria JP, Campa CC, De Santis MC, Hirsch E, Franco I (2020) The PI3K\/Akt\/mTOR pathway in polycystic kidney disease: A complex interaction with polycystins and primary cilium. Cell Signal 66:109468. https:\/\/doi.org\/10.1016\/j.cellsig.2019.109468","journal-title":"Cell Signal"},{"key":"1457_CR35","doi-asserted-by":"publisher","first-page":"9742","DOI":"10.1523\/JNEUROSCI.22-22-09742.2002","volume":"22","author":"E Molina-Holgado","year":"2002","unstructured":"Molina-Holgado E, Vela JM, Arevalo-Martin A, Almazan G, Molina-Holgado F, Borrell J, Guaza C (2002) Cannabinoids promote oligodendrocyte progenitor survival: involvement of cannabinoid receptors and phosphatidylinositol-3 kinase\/Akt signaling. J Neurosci 22:9742-9753. https:\/\/doi.org\/10.1523\/JNEUROSCI.22-22-09742.2002","journal-title":"J Neurosci"},{"key":"1457_CR36","doi-asserted-by":"publisher","first-page":"1869","DOI":"10.1210\/js.2019-00242","volume":"3","author":"H Moradi","year":"2019","unstructured":"Moradi H, Park C, Igarashi M, Streja E, Argueta DA, Soohoo M, Daglian J, You AS, Rhee CM, Kashyap ML, et al. (2019) Serum Endocannabinoid Levels in Patients With End-Stage Renal Disease. J Endocr Soc 3:1869-1880. https:\/\/doi.org\/10.1210\/js.2019-00242","journal-title":"J Endocr Soc"},{"key":"1457_CR37","doi-asserted-by":"publisher","unstructured":"Moreno E, Cavic M, Canela EI (2021) Functional Fine-Tuning of Metabolic Pathways by the Endocannabinoid System-Implications for Health and Disease. Int J Mol Sci 22. https:\/\/doi.org\/10.3390\/ijms22073661","DOI":"10.3390\/ijms22073661"},{"key":"1457_CR38","doi-asserted-by":"publisher","first-page":"e70357","DOI":"10.1111\/acel.70357","volume":"25","author":"S Morsy","year":"2026","unstructured":"Morsy S, Scifo E, Xie K, Schaaf K, Russ J, Paulusch S, De Domenico E, Salomoni P, Bano D, Ehninger D (2026) Deciphering the Transcriptomic Signatures of Aging Across Organs in Mice. Aging Cell 25:e70357. https:\/\/doi.org\/10.1111\/acel.70357","journal-title":"Aging Cell"},{"key":"1457_CR39","doi-asserted-by":"publisher","first-page":"657","DOI":"10.1111\/j.1476-5381.2010.00769.x","volume":"160","author":"P Mukhopadhyay","year":"2010","unstructured":"Mukhopadhyay P, Pan H, Rajesh M, B\u00e1tkai S, Patel V, Harvey-White J, Mukhopadhyay B, Hask\u00f3 G, Gao B, Mackie K, et al. (2010) CB1 cannabinoid receptors promote oxidative\/nitrosative stress, inflammation and cell death in a murine nephropathy model. Br J Pharmacol 160:657-668. https:\/\/doi.org\/10.1111\/j.1476-5381.2010.00769.x","journal-title":"Br J Pharmacol"},{"key":"1457_CR40","doi-asserted-by":"publisher","first-page":"825","DOI":"10.1093\/ndt\/gfab312","volume":"37","author":"RU Muller","year":"2022","unstructured":"Muller RU, Messchendorp AL, Birn H, Capasso G, Cornec-Le Gall E, Devuyst O, van Eerde A, Guirchoun P, Harris T, Hoorn EJ, et al. (2022) An update on the use of tolvaptan for autosomal dominant polycystic kidney disease: consensus statement on behalf of the ERA Working Group on Inherited Kidney Disorders, the European Rare Kidney Disease Reference Network and Polycystic Kidney Disease International. Nephrol Dial Transplant 37:825-839. https:\/\/doi.org\/10.1093\/ndt\/gfab312","journal-title":"Nephrol Dial Transplant"},{"key":"1457_CR41","doi-asserted-by":"publisher","first-page":"6497","DOI":"10.1038\/s41467-022-34255-z","volume":"13","author":"Y Muto","year":"2022","unstructured":"Muto Y, Dixon EE, Yoshimura Y, Wu H, Omachi K, Ledru N, Wilson PC, King AJ, Eric Olson N, Gunawan MG, et al. (2022) Defining cellular complexity in human autosomal dominant polycystic kidney disease by multimodal single cell analysis. Nat Commun 13:6497. https:\/\/doi.org\/10.1038\/s41467-022-34255-z","journal-title":"Nat Commun"},{"key":"1457_CR42","doi-asserted-by":"publisher","first-page":"196","DOI":"10.1016\/j.xkme.2019.11.009","volume":"2","author":"N Nobakht","year":"2020","unstructured":"Nobakht N, Hanna RM, Al-Baghdadi M, Ameen KM, Arman F, Nobahkt E, Kamgar M, Rastogi A (2020) Advances in Autosomal Dominant Polycystic Kidney Disease: A Clinical Review. Kidney Med 2:196-208. https:\/\/doi.org\/10.1016\/j.xkme.2019.11.009","journal-title":"Kidney Med"},{"key":"1457_CR43","doi-asserted-by":"publisher","first-page":"577","DOI":"10.2215\/CJN.13291019","volume":"15","author":"KL Nowak","year":"2020","unstructured":"Nowak KL, Hopp K (2020) Metabolic Reprogramming in Autosomal Dominant Polycystic Kidney Disease: Evidence and Therapeutic Potential. Clin J Am Soc Nephrol 15:577-584. https:\/\/doi.org\/10.2215\/cjn.13291019","journal-title":"Clin J Am Soc Nephrol"},{"key":"1457_CR44","doi-asserted-by":"publisher","first-page":"571","DOI":"10.1681\/ASN.2017070819","volume":"29","author":"KL Nowak","year":"2018","unstructured":"Nowak KL, You Z, Gitomer B, Brosnahan G, Torres VE, Chapman AB, Perrone RD, Steinman TI, Abebe KZ, Rahbari-Oskoui FF, et al. (2018) Overweight and Obesity Are Predictors of Progression in Early Autosomal Dominant Polycystic Kidney Disease. J Am Soc Nephrol 29:571-578. https:\/\/doi.org\/10.1681\/ASN.2017070819","journal-title":"J Am Soc Nephrol"},{"key":"1457_CR45","doi-asserted-by":"publisher","first-page":"908","DOI":"10.2215\/CJN.16871020","volume":"16","author":"KL Nowak","year":"2021","unstructured":"Nowak KL, Steele C, Gitomer B, Wang W, Ouyang J, Chonchol MB (2021) Overweight and Obesity and Progression of ADPKD. Clin J Am Soc Nephrol 16: 908-915. https:\/\/doi.org\/10.2215\/CJN.16871020","journal-title":"Clin J Am Soc Nephrol"},{"key":"1457_CR46","doi-asserted-by":"publisher","first-page":"678","DOI":"10.1038\/s41581-018-0051-1","volume":"14","author":"V Padovano","year":"2018","unstructured":"Padovano V, Podrini C, Boletta A, Caplan MJ (2018) Metabolism and mitochondria in polycystic kidney disease research and therapy. Nat Rev Nephrol 14:678-687. https:\/\/doi.org\/10.1038\/s41581-018-0051-1","journal-title":"Nat Rev Nephrol"},{"key":"1457_CR47","doi-asserted-by":"publisher","unstructured":"Permyakova A, Rothner A, Knapp S, Nemirovski A, Ben-Zvi D, Tam J (2023) Renal Endocannabinoid Dysregulation in Obesity-Induced Chronic Kidney Disease in Humans. Int J Mol Sci 24. https:\/\/doi.org\/10.3390\/ijms241713636","DOI":"10.3390\/ijms241713636"},{"key":"1457_CR48","doi-asserted-by":"publisher","first-page":"109495","DOI":"10.1016\/j.cellsig.2019.109495","volume":"67","author":"C Podrini","year":"2020","unstructured":"Podrini C, Cassina L, Boletta A (2020) Metabolic reprogramming and the role of mitochondria in polycystic kidney disease. Cell Signal 67:109495. https:\/\/doi.org\/10.1016\/j.cellsig.2019.109495","journal-title":"Cell Signal"},{"key":"1457_CR49","doi-asserted-by":"publisher","unstructured":"Portilla D, Sabapathy V, Chauss D (2025) Role of local complement activation in kidney fibrosis and repair. J Clin Invest 135. https:\/\/doi.org\/10.1172\/JCI188345","DOI":"10.1172\/JCI188345"},{"key":"1457_CR50","doi-asserted-by":"publisher","unstructured":"Reiterova J, Tesar V (2022) Autosomal Dominant Polycystic Kidney Disease: From Pathophysiology of Cystogenesis to Advances in the Treatment. Int J Mol Sci 23. https:\/\/doi.org\/10.3390\/ijms23063317","DOI":"10.3390\/ijms23063317"},{"key":"1457_CR51","doi-asserted-by":"publisher","first-page":"e0146654","DOI":"10.1371\/journal.pone.0146654","volume":"11","author":"M Riwanto","year":"2016","unstructured":"Riwanto M, Kapoor S, Rodriguez D, Edenhofer I, Segerer S, Wuthrich RP (2016) Inhibition of Aerobic Glycolysis Attenuates Disease Progression in Polycystic Kidney Disease. PLoS One 11:e0146654. https:\/\/doi.org\/10.1371\/journal.pone.0146654","journal-title":"PLoS ONE"},{"key":"1457_CR52","doi-asserted-by":"publisher","first-page":"488","DOI":"10.1038\/nm.3092","volume":"19","author":"I Rowe","year":"2013","unstructured":"Rowe I, Chiaravalli M, Mannella V, Ulisse V, Quilici G, Pema M, Song XW, Xu H, Mari S, Qian F, et al. (2013) Defective glucose metabolism in polycystic kidney disease identifies a new therapeutic strategy. Nat Med 19:488-493. https:\/\/doi.org\/10.1038\/nm.3092","journal-title":"Nat Med"},{"key":"1457_CR53","doi-asserted-by":"publisher","first-page":"F79","DOI":"10.1152\/ajprenal.00652.2014","volume":"309","author":"KM Sas","year":"2015","unstructured":"Sas KM, Yin H, Fitzgibbon WR, Baicu CF, Zile MR, Steele SL, Amria M, Saigusa T, Funk J, Bunni MA, et al. (2015) Hyperglycemia in the absence of cilia accelerates cystogenesis and induces renal damage. Am J Physiol Renal Physiol 309:F79-87. https:\/\/doi.org\/10.1152\/ajprenal.00652.2014","journal-title":"Am J Physiol Renal Physiol"},{"key":"1457_CR54","doi-asserted-by":"publisher","first-page":"3490","DOI":"10.1093\/ndt\/gfq545","volume":"25","author":"RW Schrier","year":"2010","unstructured":"Schrier RW, Levi M (2010) Lipids and renal cystic disease. Nephrol Dial Transplant 25:3490-3492. https:\/\/doi.org\/10.1093\/ndt\/gfq545","journal-title":"Nephrol Dial Transplant"},{"key":"1457_CR55","doi-asserted-by":"publisher","first-page":"820","DOI":"10.1056\/NEJMoa0907419","volume":"363","author":"AL Serra","year":"2010","unstructured":"Serra AL, Poster D, Kistler AD, Krauer F, Raina S, Young J, Rentsch KM, Spanaus KS, Senn O, Kristanto P, et al. (2010) Sirolimus and kidney growth in autosomal dominant polycystic kidney disease. N Engl J Med 363:820-829. https:\/\/doi.org\/10.1056\/NEJMoa0907419","journal-title":"N Engl J Med"},{"key":"1457_CR56","doi-asserted-by":"publisher","first-page":"5466","DOI":"10.1073\/pnas.0509694103","volume":"103","author":"JM Shillingford","year":"2006","unstructured":"Shillingford JM, Murcia NS, Larson CH, Low SH, Hedgepeth R, Brown N, Flask CA, Novick AC, Goldfarb DA, Kramer-Zucker A, et al. (2006) The mTOR pathway is regulated by polycystin-1, and its inhibition reverses renal cystogenesis in polycystic kidney disease. Proc Natl Acad Sci U S A 103:5466-5471. https:\/\/doi.org\/10.1073\/pnas.0509694103","journal-title":"Proc Natl Acad Sci U S A"},{"key":"1457_CR57","doi-asserted-by":"publisher","first-page":"2328","DOI":"10.1093\/hmg\/ddp165","volume":"18","author":"X Song","year":"2009","unstructured":"Song X, Di Giovanni V, He N, Wang K, Ingram A, Rosenblum ND, Pei Y (2009) Systems biology of autosomal dominant polycystic kidney disease (ADPKD): computational identification of gene expression pathways and integrated regulatory networks. Hum Mol Genet 18:2328-2343. https:\/\/doi.org\/10.1093\/hmg\/ddp165","journal-title":"Hum Mol Genet"},{"key":"1457_CR58","doi-asserted-by":"publisher","first-page":"109704","DOI":"10.1016\/j.cellsig.2020.109704","volume":"73","author":"X Song","year":"2020","unstructured":"Song X, Tsakiridis E, Steinberg GR, Pei Y (2020) Targeting AMP-activated protein kinase (AMPK) for treatment of autosomal dominant polycystic kidney disease. Cell Signal 73:109704. https:\/\/doi.org\/10.1016\/j.cellsig.2020.109704","journal-title":"Cell Signal"},{"key":"1457_CR59","doi-asserted-by":"publisher","first-page":"2462","DOI":"10.1073\/pnas.1011498108","volume":"108","author":"V Takiar","year":"2011","unstructured":"Takiar V, Nishio S, Seo-Mayer P, King JD, Jr., Li H, Zhang L, Karihaloo A, Hallows KR, Somlo S, Caplan MJ (2011) Activating AMP-activated protein kinase (AMPK) slows renal cystogenesis. Proc Natl Acad Sci U S A 108:2462-2467. https:\/\/doi.org\/10.1073\/pnas.1011498108","journal-title":"Proc Natl Acad Sci U S A"},{"key":"1457_CR60","doi-asserted-by":"publisher","first-page":"267","DOI":"10.1515\/jbcpp-2015-0055","volume":"27","author":"J Tam","year":"2016","unstructured":"Tam J (2016) The emerging role of the endocannabinoid system in the pathogenesis and treatment of kidney diseases. J Basic Clin Physiol Pharmacol 27:267-276. https:\/\/doi.org\/10.1515\/jbcpp-2015-0055","journal-title":"J Basic Clin Physiol Pharmacol"},{"key":"1457_CR61","doi-asserted-by":"publisher","first-page":"2953","DOI":"10.1172\/JCI42551","volume":"120","author":"J Tam","year":"2010","unstructured":"Tam J, Vemuri VK, Liu J, Batkai S, Mukhopadhyay B, Godlewski G, Osei-Hyiaman D, Ohnuma S, Ambudkar SV, Pickel J, et al. (2010) Peripheral CB1 cannabinoid receptor blockade improves cardiometabolic risk in mouse models of obesity. J Clin Invest 120:2953-2966. https:\/\/doi.org\/10.1172\/JCI42551","journal-title":"J Clin Invest"},{"key":"1457_CR62","doi-asserted-by":"publisher","first-page":"167","DOI":"10.1016\/j.cmet.2012.07.002","volume":"16","author":"J Tam","year":"2012","unstructured":"Tam J, Cinar R, Liu J, Godlewski G, Wesley D, Jourdan T, Szanda G, Mukhopadhyay B, Chedester L, Liow JS, et al. (2012) Peripheral cannabinoid-1 receptor inverse agonism reduces obesity by reversing leptin resistance. Cell Metab 16:167-179. https:\/\/doi.org\/10.1016\/j.cmet.2012.07.002","journal-title":"Cell Metab"},{"key":"1457_CR63","doi-asserted-by":"publisher","first-page":"23","DOI":"10.1016\/j.ejim.2018.01.009","volume":"49","author":"J Tam","year":"2018","unstructured":"Tam J, Hinden L, Drori A, Udi S, Azar S, Baraghithy S (2018) The therapeutic potential of targeting the peripheral endocannabinoid\/CB(1) receptor system. Eur J Intern Med 49:23-29. https:\/\/doi.org\/10.1016\/j.ejim.2018.01.009","journal-title":"Eur J Intern Med"},{"key":"1457_CR64","doi-asserted-by":"publisher","first-page":"2407","DOI":"10.1056\/NEJMoa1205511","volume":"367","author":"VE Torres","year":"2012","unstructured":"Torres VE, Chapman AB, Devuyst O, Gansevoort RT, Grantham JJ, Higashihara E, Perrone RD, Krasa HB, Ouyang J, Czerwiec FS, et al. (2012) Tolvaptan in patients with autosomal dominant polycystic kidney disease. N Engl J Med 367:2407-2418. https:\/\/doi.org\/10.1056\/NEJMoa1205511","journal-title":"N Engl J Med"},{"key":"1457_CR65","doi-asserted-by":"publisher","first-page":"1930","DOI":"10.1056\/NEJMoa1710030","volume":"377","author":"VE Torres","year":"2017","unstructured":"Torres VE, Chapman AB, Devuyst O, Gansevoort RT, Perrone RD, Koch G, Ouyang J, McQuade RD, Blais JD, Czerwiec FS, et al. (2017) Tolvaptan in Later-Stage Autosomal Dominant Polycystic Kidney Disease. N Engl J Med 377:1930-1942. https:\/\/doi.org\/10.1056\/NEJMoa1710030","journal-title":"N Engl J Med"},{"key":"1457_CR66","doi-asserted-by":"publisher","first-page":"540","DOI":"10.1016\/j.freeradbiomed.2019.11.027","volume":"152","author":"E Trojnar","year":"2020","unstructured":"Trojnar E, Erdelyi K, Matyas C, Zhao S, Paloczi J, Mukhopadhyay P, Varga ZV, Hasko G, Pacher P (2020) Cannabinoid-2 receptor activation ameliorates hepatorenal syndrome. Free Radic Biol Med 152:540-550. https:\/\/doi.org\/10.1016\/j.freeradbiomed.2019.11.027","journal-title":"Free Radic Biol Med"},{"key":"1457_CR67","doi-asserted-by":"publisher","first-page":"1063","DOI":"10.1016\/j.ekir.2025.01.023","volume":"10","author":"K Uchiyama","year":"2025","unstructured":"Uchiyama K, Kamano D, Nagasaka T, Hama EY, Shirai R, Sumura R, Kusahana E, Yanai A, Nakayama T, Kimura T, et al. (2025) Open-Label, Randomized, Controlled, Crossover Trial on the Effect of Dapagliflozin in Patients With ADPKD Receiving Tolvaptan. Kidney Int Rep 10:1063-1075. https:\/\/doi.org\/10.1016\/j.ekir.2025.01.023","journal-title":"Kidney Int Rep"},{"key":"1457_CR68","doi-asserted-by":"publisher","first-page":"3518","DOI":"10.1681\/ASN.2016101085","volume":"28","author":"S Udi","year":"2017","unstructured":"Udi S, Hinden L, Earley B, Drori A, Reuveni N, Hadar R, Cinar R, Nemirovski A, Tam J (2017) Proximal Tubular Cannabinoid-1 Receptor Regulates Obesity-Induced CKD. J Am Soc Nephrol 28:3518-3532. https:\/\/doi.org\/10.1681\/asn.2016101085","journal-title":"J Am Soc Nephrol"},{"key":"1457_CR69","doi-asserted-by":"publisher","first-page":"1437","DOI":"10.1681\/ASN.2015020132","volume":"27","author":"G Warner","year":"2016","unstructured":"Warner G, Hein KZ, Nin V, Edwards M, Chini CC, Hopp K, Harris PC, Torres VE, Chini EN (2016) Food Restriction Ameliorates the Development of Polycystic Kidney Disease. J Am Soc Nephrol 27:1437-1447. https:\/\/doi.org\/10.1681\/asn.2015020132","journal-title":"J Am Soc Nephrol"},{"key":"1457_CR70","doi-asserted-by":"publisher","first-page":"5253","DOI":"10.1038\/s41467-022-32972-z","volume":"13","author":"PC Wilson","year":"2022","unstructured":"Wilson PC, Muto Y, Wu H, Karihaloo A, Waikar SS, Humphreys BD (2022) Multimodal single cell sequencing implicates chromatin accessibility and genetic background in diabetic kidney disease progression. Nat Commun 13:5253. https:\/\/doi.org\/10.1038\/s41467-022-32972-z","journal-title":"Nat Commun"},{"key":"1457_CR71","doi-asserted-by":"publisher","first-page":"23","DOI":"10.1681\/ASN.2018090912","volume":"30","author":"H Wu","year":"2019","unstructured":"Wu H, Kirita Y, Donnelly EL, Humphreys BD (2019) Advantages of Single-Nucleus over Single-Cell RNA Sequencing of Adult Kidney: Rare Cell Types and Novel Cell States Revealed in Fibrosis. J Am Soc Nephrol 30:23-32. https:\/\/doi.org\/10.1681\/ASN.2018090912","journal-title":"J Am Soc Nephrol"}],"container-title":["Molecular Medicine"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/article\/10.1186\/s10020-026-01457-w","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s10020-026-01457-w.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s10020-026-01457-w.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,6,16]],"date-time":"2026-06-16T20:08:33Z","timestamp":1781640513000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1186\/s10020-026-01457-w"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,3,16]]},"references-count":71,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2026,12]]}},"alternative-id":["1457"],"URL":"https:\/\/doi.org\/10.1186\/s10020-026-01457-w","relation":{},"ISSN":["1528-3658"],"issn-type":[{"value":"1528-3658","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,3,16]]},"assertion":[{"value":"9 January 2026","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"6 March 2026","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"16 March 2026","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"The authors declare no competing interests.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"64"}}